Cargando…

Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate

Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of de novo/non-metastatic origin are reported in a proportion of the patient population. Where there is no evidence of metastasis or lymphatic spread, MCTs are...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Graham K., Finlay, Jessica R., Straw, Rodney C., Ziea, Joy Y., Leung, Becky, O'Connell, Kathleen, Thomson, Maurine J., Campbell, Justine E., Jones, Pamela D., Reddell, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643212/
https://www.ncbi.nlm.nih.gov/pubmed/36387404
http://dx.doi.org/10.3389/fvets.2022.1003165
_version_ 1784826471099924480
author Brown, Graham K.
Finlay, Jessica R.
Straw, Rodney C.
Ziea, Joy Y.
Leung, Becky
O'Connell, Kathleen
Thomson, Maurine J.
Campbell, Justine E.
Jones, Pamela D.
Reddell, Paul
author_facet Brown, Graham K.
Finlay, Jessica R.
Straw, Rodney C.
Ziea, Joy Y.
Leung, Becky
O'Connell, Kathleen
Thomson, Maurine J.
Campbell, Justine E.
Jones, Pamela D.
Reddell, Paul
author_sort Brown, Graham K.
collection PubMed
description Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of de novo/non-metastatic origin are reported in a proportion of the patient population. Where there is no evidence of metastasis or lymphatic spread, MCTs are effectively controlled by surgery and other local therapies. However, treatment of de novo msMCTs can be more challenging, especially when they occur in surgically difficult locations. Here, we report the use of tigilanol tiglate, a novel small molecule registered as a veterinary pharmaceutical for the local treatment of non-metastatic MCTs, in the treatment of patients with msMCTs presenting at three Australian specialist referral centres. We also present a meta-analysis of the literature to provide a better understanding of the prevalence of canine msMCTs. Notably, nine patients with a total of 32 MCTs were treated during the study. A complete response was recorded in 26 (81%) of the individual MCTs on Day 28 after a single tigilanol tiglate injection. Of the 6 initially non-responsive MCTs, one achieved a complete response after a further tigilanol tiglate treatment. A complete response was reported at 6 months in all 22 of the tumours that were evaluable and that had recorded a complete response at Day 84. For the literature meta-analysis, 22 studies were found with prevalence estimates of msMCTs ranging from 3 to 40%; when combined, these studies yielded 3,745 patients with a prevalence of 13% (95% CI 10; 16). Overall, the results demonstrate the utility of intratumoural tigilanol tiglate as an option for the treatment of multiple MCTs where multiple surgical resections would have been required.
format Online
Article
Text
id pubmed-9643212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96432122022-11-15 Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate Brown, Graham K. Finlay, Jessica R. Straw, Rodney C. Ziea, Joy Y. Leung, Becky O'Connell, Kathleen Thomson, Maurine J. Campbell, Justine E. Jones, Pamela D. Reddell, Paul Front Vet Sci Veterinary Science Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of de novo/non-metastatic origin are reported in a proportion of the patient population. Where there is no evidence of metastasis or lymphatic spread, MCTs are effectively controlled by surgery and other local therapies. However, treatment of de novo msMCTs can be more challenging, especially when they occur in surgically difficult locations. Here, we report the use of tigilanol tiglate, a novel small molecule registered as a veterinary pharmaceutical for the local treatment of non-metastatic MCTs, in the treatment of patients with msMCTs presenting at three Australian specialist referral centres. We also present a meta-analysis of the literature to provide a better understanding of the prevalence of canine msMCTs. Notably, nine patients with a total of 32 MCTs were treated during the study. A complete response was recorded in 26 (81%) of the individual MCTs on Day 28 after a single tigilanol tiglate injection. Of the 6 initially non-responsive MCTs, one achieved a complete response after a further tigilanol tiglate treatment. A complete response was reported at 6 months in all 22 of the tumours that were evaluable and that had recorded a complete response at Day 84. For the literature meta-analysis, 22 studies were found with prevalence estimates of msMCTs ranging from 3 to 40%; when combined, these studies yielded 3,745 patients with a prevalence of 13% (95% CI 10; 16). Overall, the results demonstrate the utility of intratumoural tigilanol tiglate as an option for the treatment of multiple MCTs where multiple surgical resections would have been required. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643212/ /pubmed/36387404 http://dx.doi.org/10.3389/fvets.2022.1003165 Text en Copyright © 2022 Brown, Finlay, Straw, Ziea, Leung, O'Connell, Thomson, Campbell, Jones and Reddell. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Brown, Graham K.
Finlay, Jessica R.
Straw, Rodney C.
Ziea, Joy Y.
Leung, Becky
O'Connell, Kathleen
Thomson, Maurine J.
Campbell, Justine E.
Jones, Pamela D.
Reddell, Paul
Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
title Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
title_full Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
title_fullStr Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
title_full_unstemmed Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
title_short Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
title_sort treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643212/
https://www.ncbi.nlm.nih.gov/pubmed/36387404
http://dx.doi.org/10.3389/fvets.2022.1003165
work_keys_str_mv AT browngrahamk treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT finlayjessicar treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT strawrodneyc treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT zieajoyy treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT leungbecky treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT oconnellkathleen treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT thomsonmaurinej treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT campbelljustinee treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT jonespamelad treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate
AT reddellpaul treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate